NCT06622486 is a Phase 1, PHASE2 clinical trial of EGL-001 in Solid Tumor, Adult, sponsored by Egle Therapeutics.

Who is sponsoring NCT06622486?

NCT06622486 is sponsored by Egle Therapeutics.

What drugs are being tested in NCT06622486?

Interventions in NCT06622486: EGL-001.

What condition does NCT06622486 study?

NCT06622486 studies Solid Tumor, Adult.

Is NCT06622486 still recruiting?

NCT06622486 is currently recruiting now. Last updated 7 November 2024.

Last reviewed 2024-11-07 · How we verify

NCT06622486

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors

Recruiting now Phase 1, PHASE2 Last updated 7 November 2024

What this trial tests

Phase 1, PHASE2 trial testing EGL-001 in Solid Tumor, Adult in 50 participants. Currently enrolling.

Timeline

27 September 2024

Primary endpoint
23 January 2027

23 January 2027

Quick facts

Lead sponsor	Egle Therapeutics
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	27 September 2024
Primary completion	23 January 2027
Estimated completion	23 January 2027
Sites	8 locations across France, Spain

Drugs / interventions tested

EGL-001 — full drug profile →

Conditions studied

Solid Tumor, Adult — all drugs for Solid Tumor, Adult →

Sponsor

Egle Therapeutics — full company profile →

Who can join

18 and older, any sex, with Solid Tumor, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multicenter, open-label, first-in-human, Phase 1/2 study consists of a Part 1 (Phase 1) open-label dose escalation of EGL-001 administered as a single agent and in combination with an anti-PD(L)-1 treatment, followed by a Part 2 (Phase 2) open-label dose expansion of EGL-001 administered at the RP2D in patients with recurrent and/or metastatic solid tumors as monotherapy and/or combination therapy with anti-PD(L)-1.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Solid Tumor, Adult

Currently open trials in the same condition.

NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06622486 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Egle Therapeutics
Last refreshed: 7 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06622486.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing